Glibenclamide for the treatment of acute CNS injury

Pharmaceuticals

Volumn 6, Issue 10, 2013, Pages 1287-1303

  Kurland, David B ^a   Tosun, Cigdem ^a   Pampori, Adam ^a   Karimy, Jason K ^a   Caffes, Nicholas M ^a   Gerzanich, Volodymyr ^a   Simard, J Marc ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Encephalopathy of prematurity; Glibenclamide; Metastatic brain tumor; Spinal cord injury; Sur1 Trpm4 channel; Traumatic brain injury

Indexed keywords

ALTEPLASE; DEXAMETHASONE; GLIBENCLAMIDE; GLIBORNURIDE; GLIMEPIRIDE; GLIQUIDONE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PLACEBO; RILUZOLE; RP 1127; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR 1; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INJURY; CERVICAL SPINAL CORD INJURY; DIABETES MELLITUS; DRUG MECHANISM; DRUG TARGETING; ENCEPHALOPATHY OF PREMATURITY; HUMAN; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SPINAL CORD INJURY; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

EID: 84885928862     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6101287     Document Type: Review

References (87)

1. Marble, A. Glibenclamide, a new sulphonylurea: Whither oral hypoglycaemic agents? Drugs 1971, 1, 109-115.
2. Ashcroft, F.M. Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res. 1996, 28, 456-463.
3. Feldman, J.M. Review of glyburide after one year on the market. Am. J. Med. 1985, 79, 102-108.
4. Kramer, W.; Muller, G.; Girbig, F.; Gutjahr, U.; Kowalewski, S.; Hartz, D.; Summ, H.D. The molecular interaction of sulfonylureas with β-cell ATP-sensitive K(+)-channels. Diabetes Res. Clin. Pract. 1995, 28, S67-S80.
5. Panten, U.; Schwanstecher, M.; Schwanstecher, C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp. Clin. Endocrinol. Diabetes 1996, 104, 1-9.
6. Foster, P.D.; Mamdani, M.M.; Juurlink, D.N.; Shah, B.R.; Paterson, J.M.; Gomes, T. Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006. Diabet. Med. 2013, 30, 1209-1213.
7. Woo, S.K.; Kwon, M.S.; Ivanov, A.; Gerzanich, V.; Simard, J.M. The sulfonylurea receptor 1 (Sur1)-transient receptor potential melastatin 4 (Trpm4) channel. J. Biol. Chem. 2013, 288, 3655-3667.
8. Simard, J.M.; Chen, M.; Tarasov, K.V.; Bhatta, S.; Ivanova, S.; Melnitchenko, L.; Tsymbalyuk, N.; West, G.A.; Gerzanich, V. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat. Med. 2006, 12, 433-440.
9. Simard, J.M.; Yurovsky, V.; Tsymbalyuk, N.; Melnichenko, L.; Ivanova, S.; Gerzanich, V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009, 40, 604-609.
10. Simard, J.M.; Tsymbalyuk, N.; Tsymbalyuk, O.; Ivanova, S.; Yurovsky, V.; Gerzanich, V. Glibenclamide is superior to decompressive craniectomy in a rat model of malignant stroke. Stroke 2010, 41, 531-537.
11. Simard, J.M.; Woo, S.K.; Tsymbalyuk, N.; Voloshyn, O.; Yurovsky, V.; Ivanova, S.; Lee, R.; Gerzanich, V. Glibenclamide-10-h treatment window in a clinically relevant model of stroke. Transl. Stroke Res. 2012, 3, 286-295.
12. Wali, B.; Ishrat, T.; Atif, F.; Hua, F.; Stein, D.G.; Sayeed, I. Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res. Treat. 2012, doi:10.1155/2012/460909.
13. Ortega, F.J.; Gimeno-Bayon, J.; Espinosa-Parrilla, J.F.; Carrasco, J.L.; Batlle, M.; Pugliese, M.; Mahy, N.; Rodriguez, M.J. ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Exp. Neurol. 2012, 235, 282-296.
14. Ortega, F.J.; Jolkkonen, J.; Mahy, N.; Rodriguez, M.J. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2013, 33, 356-364.
15. Simard, J.M.; Geng, Z.; Silver, F.L.; Sheth, K.N.; Kimberly, W.T.; Stern, B.J.; Colucci, M.; Gerzanich, V. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann. N. Y. Acad. Sci. 2012, 1268, 95-107.
16. Simard, J.M.; Geng, Z.; Woo, S.K.; Ivanova, S.; Tosun, C.; Melnichenko, L.; Gerzanich, V. Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2009, 29, 317-330.
17. Tosun, C.; Kurland, D.B.; Mehta, R.; Castellani, R.J.; deJong, J.L.; Kwon, M.S.; Woo, S.K.; Gerzanich, V.; Simard, J.M. Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage. Stroke 2013, in press.
18. Simard, J.M.; Kilbourne, M.; Tsymbalyuk, O.; Tosun, C.; Caridi, J.; Ivanova, S.; Keledjian, K.; Bochicchio, G.; Gerzanich, V. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. J. Neurotrauma 2009, 26, 2257-2267.
19. Patel, A.D.; Gerzanich, V.; Geng, Z.; Simard, J.M. Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. J. Neuropathol. Exp. Neurol. 2010, 69, 1177-1190.
20. Simard, J.M.; Tsymbalyuk, O.; Ivanov, A.; Ivanova, S.; Bhatta, S.; Geng, Z.; Woo, S.K.; Gerzanich, V. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J. Clin. Invest. 2007, 117, 2105-2113.
21. Simard, J.M.; Woo, S.K.; Norenberg, M.D.; Tosun, C.; Chen, Z.; Ivanova, S.; Tsymbalyuk, O.; Bryan, J.; Landsman, D.; Gerzanich, V. Brief suppression of Abcc8 prevents autodestruction of spinal cord after trauma. Sci. Transl. Med. 2010, 2, 28ra29.
22. Simard, J.M.; Popovich, P.G.; Tsymbalyuk, O.; Gerzanich, V. Spinal cord injury with unilateral versus bilateral primary hemorrhage-effects of glibenclamide. Exp. Neurol. 2012, 233, 829-835.
23. Simard, J.M.; Tsymbalyuk, O.; Keledjian, K.; Ivanov, A.; Ivanova, S.; Gerzanich, V. Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury. Exp. Neurol. 2012, 233, 566-574.
24. Tosun, C.; Koltz, M.T.; Kurland, D.B.; Ijaz, H.; Gurakar, M.; Schwartzbauer, G.; Coksaygan, T.; Ivanova, S.; Gerzanich, V.; Simard, J.M. The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci. 2013, 3, 215-238.
25. Zhou, Y.; Fathali, N.; Lekic, T.; Tang, J.; Zhang, J.H. Glibenclamide improves neurological function in neonatal hypoxia-ischemia in rats. Brain Res. 2009, 1270, 131-139.
26. Thompson, E.M.; Pishko, G.L.; Muldoon, L.L.; Neuwelt, E.A. Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. Neoplasia 2013, 15, 535-543.
27. Kunte, H.; Schmidt, S.; Eliasziw, M.; del Zoppo, G.J.; Simard, J.M.; Masuhr, F.; Weih, M.; Dirnagl, U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007, 38, 2526-2530.
28. Silver, F.L.; Fang, J.; Robertson, A.C.; Casaubon, L.; Kapral, M.K. Possible neuroprotective effects of sulfonylureas in diabetic patients with acute ischemic stroke. Stroke 2009, 40, e156.
29. Kunte, H.; Busch, M.A.; Trostdorf, K.; Vollnberg, B.; Harms, L.; Mehta, R.I.; Castellani, R.J.; Mandava, P.; Kent, T.A.; Simard, J.M. Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann. Neurol. 2012, 72, 799-806.
30. Eisenberg, E.; Banshal, V. Glyburide (RP-1127) for Traumatic Brain Injury (TBI). Available online: http://clinicaltrials.gov/show/NCT01454154 (accessed on 17 September 2013).
31. Sheth, K.N.; Kimberly, W.T. Safety Study of RP-1127 (Glyburide for Injection) in Healthy Volunteers. Available online: http://clinicaltrials.gov/show/NCT01132703 (accessed on 17 September 2013).
32. Sheth, K.N.; Kimberly, W.T. Glyburide Advantage in Malignant Edema and Stroke-Remedy Pharmaceuticals (GAMES-RP). Available online: http://clinicaltrials.gov/show/NCT01794182 (accessed on 17 September 2013).
33. Sheth, K.N. Glyburide Advantage in Malignant Edema and Stroke Pilot (GAMES-PILOT). Available online: http://clinicaltrials.gov/show/NCT01268683 (accessed on 17 September 2013).
34. Simard, J.M.; Woo, S.K.; Schwartzbauer, G.T.; Gerzanich, V. Sulfonylurea receptor 1 in central nervous system injury: A focused review. J. Cereb. Blood Flow Metab. 2012, 32, 1699-1717.
35. Simard, J.M.; Woo, S.K.; Gerzanich, V. Transient receptor potential melastatin 4 and cell death. Pflugers Arch. 2012, 464, 573-582.
36. Yamada, K.; Inagaki, N. Neuroprotection by KATP channels. J. Mol. Cell. Cardiol. 2005, 38, 945-949.
37. Thomzig, A.; Laube, G.; Pruss, H.; Veh, R.W. Pore-forming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J. Comp. Neurol. 2005, 483, 313-330.
38. Sun, H.S.; Feng, Z.P. Neuroprotective role of ATP-sensitive potassium channels in cerebral ischemia. Acta Pharmacol. Sin. 2013, 34, 24-32.
39. Simard, J.M.; Kent, T.A.; Chen, M.; Tarasov, K.V.; Gerzanich, V. Brain oedema in focal ischaemia: Molecular pathophysiology and theoretical implications. Lancet Neurol. 2007, 6, 258-268.
40. Walcott, B.P.; Kuklina, E.V.; Nahed, B.V.; George, M.G.; Kahle, K.T.; Simard, J.M.; Asaad, W.F.; Coumans, J.V. Craniectomy for malignant cerebral infarction: Prevalence and outcomes in US hospitals. PLoS One 2011, 6, e29193.
41. Lansberg, M.G.; Thijs, V.N.; Bammer, R.; Kemp, S.; Wijman, C.A.; Marks, M.P.; Albers, G.W. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007, 38, 2275-2278.
42. Lansberg, M.G.; Albers, G.W.; Wijman, C.A. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: A review of the risk factors. Cerebrovasc. Dis. 2007, 24, 1-10.
43. Shimada, I.S.; Peterson, B.M.; Spees, J.L. Isolation of locally derived stem/progenitor cells from the peri-infarct area that do not migrate from the lateral ventricle after cortical stroke. Stroke 2010, 41, e552-e560.
44. Jiang, W.; Gu, W.; Brannstrom, T.; Rosqvist, R.; Wester, P. Cortical neurogenesis in adult rats after transient middle cerebral artery occlusion. Stroke 2001, 32, 1201-1207.
45. Gu, W.; Brannstrom, T.; Wester, P. Cortical neurogenesis in adult rats after reversible photothrombotic stroke. J. Cereb. Blood Flow Metab. 2000, 20, 1166-1173.
46. Zacharia, B.E.; Hickman, Z.L.; Grobelny, B.T.; DeRosa, P.; Kotchetkov, I.; Ducruet, A.F.; Connolly, E.S., Jr. Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg. Clin. N. Am. 2010, 21, 221-233.
47. Macdonald, R.L.; Pluta, R.M.; Zhang, J.H. Cerebral vasospasm after subarachnoid hemorrhage: The emerging revolution. Nat. Clin. Pract. Neurol. 2007, 3, 256-263.
48. Simard, J.M.; Schreibman, D.; Aldrich, E.F.; Stallmeyer, B.; Le, B.; James, R.F.; Beaty, N. Unfractionated heparin: Multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. Neurocrit. Care 2010, 13, 439-449.
49. Sehba, F.A.; Pluta, R.M.; Zhang, J.H. Metamorphosis of subarachnoid hemorrhage research: From delayed vasospasm to early brain injury. Mol. Neurobiol. 2011, 43, 27-40.
50. Langlois, J.A.; Rutland-Brown, W.; Wald, M.M. The epidemiology and impact of traumatic brain injury: A brief overview. J. Head Trauma Rehabil. 2006, 21, 375-378.
51. Rao, V.; Lyketsos, C.G. Psychiatric aspects of traumatic brain injury. Psychiatr. Clin. N. Am. 2002, 25, 43-69.
52. Chang, E.F.; Meeker, M.; Holland, M.C. Acute traumatic intraparenchymal hemorrhage: Risk factors for progression in the early post-injury period. Neurosurgery 2006, 58, 647-656.
53. Oertel, M.; Kelly, D.F.; McArthur, D.; Boscardin, W.J.; Glenn, T.C.; Lee, J.H.; Gravori, T.; Obukhov, D.; McBride, D.Q.; Martin, N.A. Progressive hemorrhage after head trauma: Predictors and consequences of the evolving injury. J. Neurosurg. 2002, 96, 109-116.
54. Servadei, F.; Nanni, A.; Nasi, M.T.; Zappi, D.; Vergoni, G.; Giuliani, G.; Arista, A. Evolving brain lesions in the first 12 hours after head injury: Analysis of 37 comatose patients. Neurosurgery 1995, 37, 899-906.
55. Smith, J.S.; Chang, E.F.; Rosenthal, G.; Meeker, M.; von, Koch, C.; Manley, G.T.; Holland, M.C. The role of early follow-up computed tomography imaging in the management of traumatic brain injury patients with intracranial hemorrhage. J. Trauma 2007, 63, 75-82.
56. Kurland, D.; Hong, C.; Aarabi, B.; Gerzanich, V.; Simard, J.M. Hemorrhagic progression of a contusion after traumatic brain injury: A review. J. Neurotrauma 2012, 129, 19-31.
57. Narayan, R.K.; Maas, A.I.; Marshall, L.F.; Servadei, F.; Skolnick, B.E.; Tillinger, M.N. Recombinant factor VIIA in traumatic intracerebral hemorrhage: Results of a dose-escalation clinical trial. Neurosurgery 2008, 62, 776-786.
58. Hackenberg, K.; Zweckberger, K.; Sakowitz, O.; Jung, C.; Unterberg, A.W. Glibenclamide Reduces Secondary Brain Damage after Experimental Traumatic Brain Injury. In Proceedings of 64th Annual Meeting of the German Society of Neurosurgery (DGNC), Düsseldorf, Germany, 26-29 May 2013.
59. Bilgen, M.; Abbe, R.; Liu, S.J.; Narayana, P.A. Spatial and temporal evolution of hemorrhage in the hyperacute phase of experimental spinal cord injury: In vivo magnetic resonance imaging. Magn. Reson. Med. 2000, 43, 594-600.
60. Hayes, K.C.; Kakulas, B.A. Neuropathology of human spinal cord injury sustained in sports-related activities. J. Neurotrauma. 1997, 14, 235-248.
61. Kwon, B.K.; Tetzlaff, W.; Grauer, J.N.; Beiner, J.; Vaccaro, A.R. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 2004, 4, 451-464.
62. Tator, C.H.; Fehlings, M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 1991, 75, 15-26.
63. Fitch, M.T.; Doller, C.; Combs, C.K.; Landreth, G.E.; Silver, J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: In vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci. 1999, 19, 8182-8198.
64. Krause, E. Advances in Fluid Mechanics-Proceedings of a Conference Held at Aachen, Germany, 26-28 March, 1980; Springer: Berlin, Germany, 1981.
65. Nelson, E.; Gertz, S.D.; Rennels, M.L.; Ducker, T.B.; Blaumanis, O.R. Spinal cord injury. The role of vascular damage in the pathogenesis of central hemorrhagic necrosis. Arch. Neurol. 1977, 34, 332-333.
66. Tator, C.H. Review of experimental spinal cord injury with emphasis on the local and systemic circulatory effects. Neurochirurgie 1991, 37, 291-302.
67. Tator, C.H.; Koyanagi, I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J. Neurosurg. 1997, 86, 483-492.
68. Balentine, J.D. Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab. Invest. 1978, 39, 236-253.
69. Kawata, K.; Morimoto, T.; Ohashi, T.; Tsujimoto, S.; Hoshida, T.; Tsunoda, S.; Sakaki, T. Experimental study of acute spinal cord injury: A histopathological study. No Shinkei Geka 1993, 21, 45-51.
70. Griffiths, I.R.; Burns, N.; Crawford, A.R. Early vascular changes in the spinal grey matter following impact injury. Acta Neuropathol. 1978, 41, 33-39.
71. Kapadia, S.E. Ultrastructural alterations in blood vessels of the white matter after experimental spinal cord trauma. J. Neurosurg. 1984, 61, 539-544.
72. Popovich, P.G.; Lemeshow, S.; Gensel, J.C.; Tovar, C.A. Independent evaluation of the effects of glibenclamide on reducing progressive hemorrhagic necrosis after cervical spinal cord injury. Exp. Neurol. 2012, 233, 615-622.
73. Fehlings, M.G.; Wilson, J.R.; Frankowski, R.F.; Toups, E.G.; Aarabi, B.; Harrop, J.S.; Shaffrey, C.I.; Harkema, S.J.; Guest, J.D.; Tator, C.H. Riluzole for the treatment of acute traumatic spinal cord injury: Rationale for and design of the NACTN Phase I clinical trial. J. Neurosurg. Spine 2012, 17, 151-156.
74. Wilson, J.R.; Fehlings, M.G. Riluzole for acute traumatic spinal cord injury: A promising neuroprotective treatment strategy. World Neurosurg. 2013, doi:10.1016/j.wneu.2013.01.001.
75. Aarnoudse-Moens, C.S.; Weisglas-Kuperus, N.; van Goudoever, J.B.; Oosterlaan, J. Meta-analysis of neurobehavioral outcomes in very preterm and/or very low birth weight children. Pediatrics 2009, 124, 717-728.
76. Bassan, H.; Limperopoulos, C.; Visconti, K.; Mayer, D.L.; Feldman, H.A.; Avery, L.; Benson, C.B.; Stewart, J.; Ringer, S.A.; Soul, J.S. Neurodevelopmental outcome in survivors of periventricular hemorrhagic infarction. Pediatrics 2007, 120, 785-792.
77. Doyle, L.W.; Anderson, P.J. Adult outcome of extremely preterm infants. Pediatrics 2010, 126, 342-351.
78. Volpe, J.J. Neurologic outcome of prematurity. Arch. Neurol. 1998, 55, 297-300.
79. Simard, J.M.; Castellani, R.J.; Ivanova, S.; Koltz, M.T.; Gerzanich, V. Sulfonylurea receptor 1 in the germinal matrix of premature infants. Pediatr. Res. 2008, 64, 648-652.
80. Yager, J.Y.; Ashwal, S. Animal models of perinatal hypoxic-ischemic brain damage. Pediatr. Neurol. 2009, 40, 156-167.
81. Koltz, M.T.; Tosun, C.; Kurland, D.B.; Coksaygan, T.; Castellani, R.J.; Ivanova, S.; Gerzanich, V.; Simard, J.M. Tandem insults of prenatal ischemia plus postnatal raised intrathoracic pressure in a novel rat model of encephalopathy of prematurity. J. Neurosurg. Pediatr. 2011, 8, 628-639.
82. Thomalla, G.; Hartmann, F.; Juettler, E.; Singer, O.C.; Lehnhardt, F.G.; Kohrmann, M.; Kersten, J.F.; Krutzelmann, A.; Humpich, M.C.; Sobesky, J. Prediction of malignant middle cerebral artery infarction by magnetic resonance imaging within 6 hours of symptom onset: A prospective multicenter observational study. Ann. Neurol. 2010, 68, 435-445.
83. Mlynash, M.; Lansberg, M.G.; de Silva, D.A.; Lee, J.; Christensen, S.; Straka, M.; Campbell, B.C.; Bammer, R.; Olivot, J.M.; Desmond, P. Refining the definition of the malignant profile: Insights from the DEFUSE-EPITHET pooled data set. Stroke 2011, 42, 1270-1275.
84. Vahedi, K.; Hofmeijer, J.; Juettler, E.; Vicaut, E.; George, B.; Algra, A.; Amelink, G.J.; Schmiedeck, P.; Schwab, S.; Rothwell, P.M. Early decompressive surgery in malignant infarction of the middle cerebral artery: A pooled analysis of three randomised controlled trials. Lancet Neurol. 2007, 6, 215-222.
85. Sanak, D.; Nosal', V.; Horak, D.; Bartkova, A.; Zelenak, K.; Herzig, R.; Bucil, J.; Skoloudik, D.; Burval, S.; Cisarikova, V. Impact of diffusion-weighted MRI-measured initial cerebral infarction volume on clinical outcome in acute stroke patients with middle cerebral artery occlusion treated by thrombolysis. Neuroradiology 2006, 48, 632-639.
86. Tomiyama, Y.; Brian, J.E., Jr.; Todd, M.M. Cerebral blood flow during hemodilution and hypoxia in rats: Role of ATP-sensitive potassium channels. Stroke 1999, 30, 1942-1947.
87. Liss, B.; Roeper, J. Molecular physiology of neuronal K-ATP channels (review). Mol. Membr. Biol. 2001, 18, 117-127.